The board of directors approved an increase in size from seven to eight members and appointed Jeffrey Farrow as a Class III director effective October 13, 2026. Mr. Farrow joins the Audit Committee and brings extensive experience as CFO of multiple biopharmaceutical companies, including Tarsus Pharmaceuticals, Global Blood Therapeutics, ZS Pharma, and Hyperion Therapeutics. He is classified as an independent director under Nasdaq listing rules. Lisata Therapeutics operates in the clinical-stage pharmaceutical industry, developing treatments for severe hypertriglyceridemia and acromegaly.
